ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Appili Therapeutics Inc

Appili Therapeutics Inc (APLI)

0,035
0,005
(16,67%)
Fermé 08 Février 10:12PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
0,035
Prix Achat
0,03
Prix Vente
0,035
Volume échangé
5 000
0,035 Fourchette du Jour 0,035
0,025 Plage de 52 semaines 0,06
Cap du marché
Clôture Veille
0,03
Ouverture
0,035
Dernière Transaction
5000
@
0.035
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
68 706
Actions en circulation
121 266 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,96
Bénéfice par action (BPA)
-0,03
Chiffre d'affairess
6,69M
Bénéfice net
-3,78M

À propos de Appili Therapeutics Inc

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Halifax, Nova Scotia, Can
Fondé
-
Appili Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la Toronto Stock Exchange avec le ticker APLI. Le dernier cours de clôture d'Appili Therapeutics était de $0,03. Au cours de la dernière année, les actions de Appili Therapeutics ont été négociées dans une fourchette de prix de $ 0,025 à $ 0,06.

Appili Therapeutics compte actuellement 121 266 000 actions en circulation. La capitalisation boursière d'Appili Therapeutics est de $3,64 million. Appili Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.96.

APLI Dernières nouvelles

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”...

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1000.0350.0350.03243000.03428807CS
4000.0350.040.03426110.03472139CS
120.00516.66666666670.030.0450.03687060.03412664CS
26000.0350.0450.025831180.03378955CS
520.00516.66666666670.030.060.0251207280.0376192CS
156-0.095-73.07692307690.130.170.0251486780.05503998CS
260-1.095-96.90265486731.131.60.0251603350.27209787CS

APLI - Frequently Asked Questions (FAQ)

What is the current Appili Therapeutics share price?
The current share price of Appili Therapeutics is $ 0,035
How many Appili Therapeutics shares are in issue?
Appili Therapeutics has 121 266 000 shares in issue
What is the market cap of Appili Therapeutics?
The market capitalisation of Appili Therapeutics is CAD 3,64M
What is the 1 year trading range for Appili Therapeutics share price?
Appili Therapeutics has traded in the range of $ 0,025 to $ 0,06 during the past year
What is the PE ratio of Appili Therapeutics?
The price to earnings ratio of Appili Therapeutics is -0,96
What is the cash to sales ratio of Appili Therapeutics?
The cash to sales ratio of Appili Therapeutics is 0,54
What is the reporting currency for Appili Therapeutics?
Appili Therapeutics reports financial results in CAD
What is the latest annual turnover for Appili Therapeutics?
The latest annual turnover of Appili Therapeutics is CAD 6,69M
What is the latest annual profit for Appili Therapeutics?
The latest annual profit of Appili Therapeutics is CAD -3,78M
What is the registered address of Appili Therapeutics?
The registered address for Appili Therapeutics is 21-1344 SUMMER STREET, HALIFAX, NOVA SCOTIA, B3H 0A8
What is the Appili Therapeutics website address?
The website address for Appili Therapeutics is www.appilitherapeutics.com
Which industry sector does Appili Therapeutics operate in?
Appili Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BNGBengal Energy Ltd
$ 0,01
(100,00%)
46,6k
CTSConverge Technology Solutions Corp
$ 5,42
(53,54%)
14,22M
RTGRTG Mining Inc
$ 0,03
(20,00%)
86k
WLLWWillow Biosciences Inc
$ 0,03
(20,00%)
2,4k
AMCArizona Metals Corp
$ 1,51
(17,05%)
845,01k
ELEFSilver Elephant Mining Corp
$ 0,185
(-33,93%)
111,64k
WEEDCanopy Growth Corporation
$ 2,90
(-27,32%)
4,89M
XLYAuxly Cannabis Group Inc
$ 0,055
(-15,38%)
6,8M
MUXMcEwen Mining Inc
$ 10,54
(-15,00%)
249,71k
GRCGold Springs Resource Corp
$ 0,06
(-14,29%)
60k
CTSConverge Technology Solutions Corp
$ 5,42
(53,54%)
14,22M
MFCManulife Financial Corporation
$ 43,06
(0,35%)
10,83M
ENBEnbridge Inc
$ 63,52
(0,17%)
10,13M
GLOGlobal Atomic Corporation
$ 0,47
(-11,32%)
9,24M
SUSuncor Energy Inc
$ 55,35
(0,65%)
9,02M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock